EGFR and neoplasm: In a preclinical study using syngeneic and GEM models, it was shown that the combination of Epidermal Growth Factor Receptor (EGFR)-peptide vaccine and an antagonist of glutamine utilizing enzymes is more effective in decreasing tumor burden and increasing anti-tumor immune responses compared to either agents alone [87].